Safe BPC-157

Research digest / sources

BPC-157 References and Citations

Every quantitative claim on this site maps to one of these sources — the peer-reviewed studies, the human pilots, the 2025 reviews, and the FDA regulatory record.

Back to the researchBack to the legal status

How to use this list

These BPC-157 references are the full source set for the site. Citations [1] through [17] are the peer-reviewed research record — animal studies, pharmacokinetics, mechanism papers, the human pilot studies, and the 2025 reviews. Citations [20] through [25] are the regulatory sources used on the legal status page; they are FDA pages (plus one law-firm analysis) verified against the live source, used only for present-tense regulatory facts.

Each entry carries a DOI or a PubMed link where one exists. Where a paper is animal work, the body copy says so; the citation here is the verifiable anchor for that claim.

A note on the evidence base

Two structural facts are worth keeping in view while reading the list. First, the great majority of these citations are preclinical — rats, dogs, and cell models — and only a few ([11], [13]) involve humans, all of them small pilots. Second, a large share of the foundational work originates from a single research group, which the 2025 reviews ([12], [16]) note when calling for independent replication. The citations are real and checkable; the weight any one of them can bear is the judgment this site tries to make explicit.

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. ↗
  3. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. ↗
  4. Xue XC, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. World J Gastroenterol. 2004;10(7):1032-1037. ↗
  5. Gjurasin M, et al. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regul Pept. 2010;160(1-3):33-41. ↗
  6. Novel Therapeutic Effects in Rat Spinal Cord Injuries: Recovery of the Definitive and Early Spinal Cord Injury by the Application of Pentadecapeptide BPC 157 Therapy. Curr Issues Mol Biol. 2022;44(5):1901-1927. ↗
  7. Sikiric P, et al. The antidepressant effect of an antiulcer pentadecapeptide BPC 157 in Porsolt's test and chronic unpredictable stress in rats. A comparison with antidepressants. J Physiol Paris. 2000;94(2):99-104. ↗
  8. Boban Blagaic A, et al. Gastric pentadecapeptide BPC 157 effective against serotonin syndrome in rats. Eur J Pharmacol. 2005;512(2-3):173-179. ↗
  9. Tohyama Y, et al. Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain: alpha-methyltryptophan autoradiographic measurements. Life Sci. 2004;76(3):345-357. ↗
  10. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. ↗
  11. McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  12. Human pilot data on BPC-157, as summarized in McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (Curr Rev Musculoskelet Med. 2025), describing three small human pilot studies: a 2-participant intravenous safety pilot, an intra-articular knee-pain case series, and a 12-patient intravesical interstitial-cystitis pilot. ↗
  13. Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Acute Pancreatitis. Medicina (Kaunas). 2025;61(2):291. ↗
  14. Multifunctionality and Possible Medical Application of the BPC 157 Peptide - Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. ↗
  15. Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Effect Following Intoxications. Pharmaceuticals (Basel). 2025;18(6):928. ↗
  16. Concerning BPC-157, a natural pentadecapeptide, that acts as a cytoprotectant. Inflammopharmacology. 2025. ↗
  17. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA.gov (verified 2026-05-29). Defines Category 1 and Category 2 and the bulks-list nomination framework. ↗
  18. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA.gov advisory-committee calendar (verified 2026-05-29). Lists BPC-157, KPV, TB-500, and MOTs-C as substances being considered for inclusion on the 503A Bulks List. ↗
  19. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. FDA.gov (entry effective 2023-09-29; verified 2026-05-29). Source of the BPC-157 (free base / acetate) Category 2 placement and the stated safety rationale. ↗
  20. U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act (guidance landing page). FDA.gov (guidance finalized January 2025; verified 2026-05-29). ↗
  21. Access-pathway framework for legally compounded medications under sections 503A and 503B of the FD&C Act (licensed-prescriber evaluation, including compliant telehealth, leading to a valid patient-specific prescription dispensed by a state-licensed 503A pharmacy or sourced from an FDA-registered 503B outsourcing facility; bulk-ingredient eligibility required), as synthesized from FDA compounding guidance. FDA.gov (verified 2026-05-29). ↗